GLP-1 agonists in type 2 diabetes
Rybelsus (semaglutide) is a daily oral GLP-1 agonist for Type 2 diabetes that has A1C lowering as strong as injected Victoza (liraglutide) 1.8mg and somewhat better weight loss (-4.4kg versus -3.1kg to week 26), with similar gastrointestinal side effects. For proper oral absorption, it must be taken at least 30 minutes before the first food, beverage, or other oral medications of the day.
- In which patients, line of therapy, or other situations do you use Rybelsus as compared to injectable GLP-1 agonists, and when do you use an injectable GLP-1 agonist instead?
- In which patients, lines of therapy, or other situations do you prefer other oral classes of agents, besides metformin, to Rybelsus and why?